RxDoctor Payments Data

Trent Pettijohn, MD

Interventional Cardiology · Plano, TXNPI 1265468706

Payments from drug & device makers

$3,187in general payments, 2019–2025

Across 170 payments — averaging $18.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Amgen$316
  • Pfizer$192
  • Amarin Pharma, Inc.$171
  • Boehringer Ingelheim$164
  • Sanofi-aventis U.S. LLC$162
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$3,173100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,187 in reported general payments places this provider in the 15th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$373,801
Medicare patients
1,160
Services billed
4,047

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban769$851,351
XareltoRivaroxaban173$228,441
Repatha SureclickEvolocumab143$142,143
EntrestoSacubitril/Valsartan93$95,914
Praluent PenAlirocumab42$23,489
BrilintaTicagrelor19$12,185
Metoprolol Succinate964$12,098
Ranolazine ErRanolazine107$10,866
Ezetimibe431$9,863
Atorvastatin Calcium1,187$8,851
Rosuvastatin Calcium620$6,171
Valsartan194$6,045
Carvedilol709$5,998
Olmesartan Medoxomil327$5,970
Dabigatran EtexilateDabigatran Etexilate Mesylate13$5,131

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$192$851,351769 claims
Johnson & JohnsonXarelto$158$228,441173 claims
NovartisEntresto$1,104$95,91493 claims
AstraZenecaBrilinta$143$12,18519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →